Potential Dissociative Glucocorticoid Receptor Activity for Protopanaxadiol and Protopanaxatriol by Karra, Aikaterini G et al.
Article
Potential Dissociative Glucocorticoid Receptor Activity 
for Protopanaxadiol and Protopanaxatriol
Karra, Aikaterini G, Konstantinou, Maria, Tzortziou, Maria, Tsialtas, 
Ioannis, Kalousi, Foteini D, Garagounis, Constantine, Hayes, Joseph 
M and Psarra, Anna-Maria G
Available at http://clok.uclan.ac.uk/25746/
Karra, Aikaterini G, Konstantinou, Maria, Tzortziou, Maria, Tsialtas, Ioannis, Kalousi, Foteini D,  
Garagounis, Constantine, Hayes, Joseph M ORCID: 0000­0002­7745­9616 and Psarra, Anna­
Maria G (2018) Potential Dissociative Glucocorticoid Receptor Activity for Protopanaxadiol and 
Protopanaxatriol. International Journal of Molecular Sciences, 20 (1). p. 94. ISSN 1661­6596  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.3390/ijms20010094
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
 International Journal of 
Molecular Sciences
Article
Potential Dissociative Glucocorticoid Receptor
Activity for Protopanaxadiol and Protopanaxatriol
Aikaterini G. Karra 1, Maria Konstantinou 1, Maria Tzortziou 1, Ioannis Tsialtas 1,
Foteini D. Kalousi 1, Constantine Garagounis 1, Joseph M. Hayes 2 and Anna-Maria G. Psarra 1,*
1 Department of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece;
Aikaterini.g.karra@gmail.com (A.G.K.); maira_kman_91@hotmail.com (M.K.); matziort@bio.uth.gr (M.T.)
itsialtas@bio.uth.gr (I.T.); fokalous@bio.uth.gr (F.D.K.); constantine.garagounis@gmail.com (C.G.)
2 School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR12HE, UK;
JHayes@uclan.ac.uk
* Correspondence: ampsarra@bio.uth.gr; Tel.: +30-2410-565221
Received: 23 October 2018; Accepted: 21 December 2018; Published: 27 December 2018


Abstract: Glucocorticoids are steroid hormones that regulate inflammation, growth, metabolism,
and apoptosis via their cognate receptor, the glucocorticoid receptor (GR). GR, acting mainly as
a transcription factor, activates or represses the expression of a large number of target genes,
among them, many genes of anti-inflammatory and pro-inflammatory molecules, respectively.
Transrepression activity of glucocorticoids also accounts for their anti-inflammatory activity,
rendering them the most widely prescribed drug in medicine. However, chronic and high-dose
use of glucocorticoids is accompanied with many undesirable side effects, attributed predominantly
to GR transactivation activity. Thus, there is a high need for selective GR agonist, capable of
dissociating transrepression from transactivation activity. Protopanaxadiol and protopanaxatriol are
triterpenoids that share structural and functional similarities with glucocorticoids. The molecular
mechanism of their actions is unclear. In this study applying induced-fit docking analysis, luciferase
assay, immunofluorescence, and Western blot analysis, we showed that protopanaxadiol and more
effectively protopanaxatriol are capable of binding to GR to activate its nuclear translocation, and to
suppress the nuclear factor-kappa beta activity in GR-positive HeLa and HEK293 cells, but not
in GR-low level COS-7 cells. Interestingly, no transactivation activity was observed, whereas
suppression of the dexamethasone-induced transactivation of GR and induction of apoptosis in HeLa
and HepG2 cells were observed. Thus, our results indicate that protopanaxadiol and protopanaxatriol
could be considered as potent and selective GR agonist.
Keywords: protopanaxadiol; protopanaxatriol; glucocorticoid receptor; SEGRA; apoptosis;
inflammation; ginsenosides; tranactivation; tranrepression
1. Introduction
Glucocorticoids (GCs) are steroid hormones which exert their actions via binding to their cognate
receptors, the glucocorticoid receptors (GRs). Glucocorticoid receptors belong to the large superfamily
of nuclear receptors that act mainly as transcription factors [1]. GCs control many cellular functions
such as metabolism, growth, development, immune and stress response, apoptosis, and glucose
homeostasis [2]. The glucocorticoid receptor alpha (GR) is the most prominent transcriptionally
active isoform of GRs. GR is predominantly localized in the cytoplasm. Upon ligand binding, GR is
translocated into the nucleus where it positively or negatively regulates the transcription of a plethora
of GR target genes, either by direct binding to specific hormone response elements of the nuclear
DNA, or by interaction with other transcription factors and regulation of their target genes expression.
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GCs can also act by nongenomic, mechanisms of action, via activation of cytosolic or membrane-bound
GR, such as membranous G-coupled glucocorticoid receptor, or via nonspecific physicochemical
interactions with cell membrane [3–6]. Mitochondrial glucocorticoid receptor localization and direct or
indirect regulation of mitochondrial actions via GCs are also documented [7–10].
Due to the crucial role of GCs in the regulation of human physiology and especially due to their
strong anti-inflammatory, immunosuppressive and tissue-specific apoptotic activities, GCs are widely
used for the treatment of acute and chronic inflammatory diseases, autoimmune diseases [11,12],
as well as for the treatment of many oncology disorders such as hematopoietic malignancies of
the lymphoid lineage [13,14]. The anti-inflammatory and immunosuppressive effects of GCs are
exerted via (a) the activation of GCs transrepression activities, which are mediated by the negative
glucocorticoid response element (GRE) dependent regulation of pro-inflammatory GR target genes
expression, (b) via interaction of GR with other transcriptions factors such as Nuclear factor-kappa beta
(NF-κB) and Signal Transducer and Activator of Transcription-3 (Stat3) and regulation of their actions,
and (c) via activation of GRE–dependent transcription of many anti-inflammatory molecules [15,16].
On the other hand, the supra-physiological doses and chronic use of exogenous GCs, for medical
purposes, often gives rise to many undesirable side effects, including diabetes induction, muscle
wasting, and fat redistribution, effects associated with the GCs-induced gluconeogenesis and activation
of catabolic actions such as lipolysis and protein degradation [17–19]. These actions are mostly
mediated by GR transactivation, whereas GR transrepression is responsible for the side effect of
hypothalamic pituitary axis (HPA) suppression, observed by steroids treatment. In addition, other
side effects such as osteoporosis are mediated by both transactivation and transrepression [20].
Thus, there is a high need for potent selective steroidal or non-steroidal glucocorticoid
receptor agonist (SEGRAs) or modulators (SEGRMs) that possess the desirable anti-inflammatory,
immunosuppressive or anti-cancer activities of the classic GCs, but exert no or reduced side
effects [20–24]. These compounds can bind to the same or to different GCs binding sites in the
ligand binding domain (LBD) of GR. Binding of GR with these molecules may cause different
GR conformational changes, affecting GR binding to DNA and/or recruitment of corepressors or
coactivators in the GR-ligand complex, leading to modulation of GR functions [20].
Triterpenoids, that share structural similarities with GCs proved to be potent and selective
glucocorticoid receptor modulators. Experimental observations showed that triterpenoids, such
as avidin D [25], echynocystic acid and its 3-O-glucoside derivative [26], induced GR nuclear
translocation and GR transrepressional activities with no or limited GR transactivation. Some reports
also demonstrate the ability of protopanaxadiol (PPD) and protopanaxatriol (PPT) to bind to
nuclear receptors, such as estrogen and glucocorticoid receptor, and to control their actions [27,28].
Protopanaxadiol and protopanaxatriol share a dammarane-type tetracyclic terpene and belongs
to the family of saponin triterpenoids, known as ginsenosides. Ginsenosides can be classified
as protopanaxadiol-type or protopanaxatriol-type compounds which differ in the position, sugar
substituents, and number of glycosyl attachments to the dammarane steroid backbone. PPD and PPT
correspond to the aglycone form of the compounds. Furthermore, the C-20 of protopanaxadiol and
protopanaxatriol is divided into 20(S) and 20(R)-type structures, depending on the position of the
chiral carbon substitution [29] (Figure 1). Over 30 ginsenosides have been identified and classified
into these two categories, among them the Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2, Rs1 (the 20(S)-type
protopanaxadiol) and the Re, Rf, Rg1, Rg2, Rh1 (the 20(S)-type protopanaxadiol [30]. The ability of
ginsenosides to regulate the non-genomic effect of GR is also proposed [27]. Nevertheless, there
is a controversy on whether PPD and PPT can regulate the genomic actions of glucocorticoid
receptor [28]. Interestingly, PPD- and PPT- type ginsenosides are widely used for medicinal
purposes, due to their pharmaceuticals activities, some of them similar to that of the glucocorticoids
hormones. Thus, increasing numbers of studies reveal their potent anti-inflammatory, antidiabetic,
cardioprotective, and apoptotic activities (reviewed by [29,31]). Nevertheless, the molecular and
biochemical mechanisms of their pharmaceutical actions are unclear and not defined.
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In this study the efficacy of the PPD and PPT compound to exert dissociative glucocorticoid like
activity was examined in human HeLa, HEK293 and HepG2 cells, via assessment on their effect on GR
potential binding, nuclear translocation, regulation of GR transactivation and transrepression activities
and induction of apoptosis.
Int. J. Mol. Sci. 2018, 19, x 3 of 19 
 
In this study the efficacy of the PPD and PPT compound to exert dissociative glucocorticoid like 
activity was examined in human HeLa, HEK293 and HepG2 cells, via assessment on their effect on 
GR potential binding, nuclear translocation, regulation of GR transactivation and transrepression 
activities and induction of apoptosis. 
3 33
8 8
6
8
17 17
14
21
14
12
2020
121311
10
17
10 10
PPDDEX PPT
 
Figure 1. Chemical structures of the synthetic glucocorticoid DEX, a GR agonist, and the triterpenoids 
(20S)-Protopanaxadiol (PPD) and (20S)-Protopanaxatriol (PPT) studied in this work. 
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dexamethasone (DEX) (Figure 1), prompted us to examine the potential binding of PPD and PPT to 
the GR ligand binding domain (LBD), applying induced-fit docking analysis (IFD). For comparative 
purposes, therefore, DEX was also considered in these calculations. There are numerous examples of 
IFD used to successfully predict ligand-induced protein conformational changes and the effects on 
biochemical pathways in agreement with experiment [26,32–35], including for GR [26]. The results of 
the IFD are shown in Table 1, with both PPD and PPT predicted to bind well. The GlideScores are 
strong at ~ −15 and close to those of DEX (−15.59), while the IFDScores (−557.7 and −560.8 for PPD 
and PPT, respectively), that additionally take the protein energy/conformation into account, are in 
fact predicted better than for DEX (−551.7). 
Table 1. Induced-fit docking calculation results a. 
Ligand GlideScore IFDscore 
DEX a −15.59 −551.7 
PPD b −14.93 −557.7 
PPT c −15.23 −560.8 
a Top-ranked pose based on IFDScore which had a ligand heavy atom RMSD (root-
mean-square deviation) just 0.610 Å compared with its crystallographic 
conformation (PDB code: 1M2Z). The RMSD was calculated by overlapping the 
predicted complex against 1M2Z by matching the residue backbone atoms of 
helices H5 and H8 [36]. b Fourth ranked IFDScore pose: exhibited interactions in the 
LBD favorable for nuclear translocation [26,36]. For comparison, the top ranked 
PPD protein-ligand pose had a GlideScore and IFDScore of −13.89 and −558.6, 
respectively, and hence had less favorable interactions in the LBD based on 
GlideScore. c Top-ranked pose based on the IFDscore: exhibited binding 
characteristics consistent with nuclear translocation [26,36]. 
Figure 1. Chemical structures of the synthetic glucocorticoid DEX, a GR agonist, and the triterpenoids
(20S)-Protopanaxadiol (PPD) and (20S)-Protopanaxatriol (PPT) studied in this work.
2. Results
2.1. Induced-Fit Docking Analysis Reveals Potential Binding of PPD and PPT to GR Ligand Binding Domain
Structural similarities of PPD and PPT with the natural cortisol and the synthetic corticosteroid,
dexamethasone (DEX) (Figure 1), prompted us to examine the potential binding of PPD and PPT to
the GR ligand binding domain (LBD), applying induced-fit docking analysis (IFD). For comparative
purposes, therefore, DEX was also considered in these calculations. There are numerous examples of
IFD used to successfully predict ligand-induced protein conformational changes and the effects on
biochemical pathways in agreement with experiment [26,32–35], including for GR [26]. The results
of the IFD are shown in Table 1, with both PPD and PPT predicted to bind well. The GlideScores are
strong at ~ −15 and close to those of DEX (−15.59), while the IFDScores (−557.7 and −560.8 for PPD
and PPT, respectively), that additionally take the protein energy/conformation into account, are in fact
predicted better than for DEX (−551.7).
Table 1. Induced-fit docking calculation results a.
Ligand GlideScore IFDScore
DEX a −15.59 −551.7
PPD b −14.93 −557.7
PPT c −15.23 −560.8
a Top-ranked pose based on IFDScore which had a ligand heavy atom RMSD (root-mean-square deviation) just
0.610 Å compared with its crystallographic conformation (PDB code: 1M2Z). The RMSD was calculated by
overlapping the predicted complex against 1M2Z by matching the residue backbone atoms of helices H5 and
H8 [36]. b Fourth ranked IFDScore pose: exhibited interactions in the LBD favorable for nuclear translocation [26,36].
For comparison, the top ranked PPD protein-ligand pose had a GlideScore and IFDScore of −13.89 and −558.6,
respectively, and hence had less favorable interactions in the LBD based on GlideScore. c Top-ranked pose based on
the IFDScore: exhibited binding characteristics consistent with nuclear translocation [26,36].
The predicted binding interacti ns of PPD and PPT are shown in Figure 2. Both ligands occupy
close to the same space as DEX, although the rings are not co-planar with DEX. In comparison,
the RMSD between ring atoms of PPD and PPT is just 0.609 Å (aligned by superimposition of helices
H5 and H8 backbone atoms [36]). The C-3 hydroxyl groups of both ligands exploit similar interactions
to that of the DEX C-3 ketone group forming hydr gen bonds with Gln570 (H3) and Arg611 (H5).
They are predicted to form an additional hydrogen bond with the Phe623 backbone O (β-strand
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between H5 and H6). The C-12 hydroxyls for both PPD and PPT are involved in important hydrogen
bond interactions with the Gln642 (H7) sidechain. For PPT, the hydrogen bond is with the sidechain
amide C=O similar to that formed by DEX through its C-17 hydroxyl. However, for PPD there is a
flip in the Gln642 sidechain so that the hydrogen bond is instead between the sidechain NH2 and the
C-12 hydroxyl O atom. This frees the C-12 hydroxyl H atom to form an intra-molecular hydrogen
bond with the C-20 hydroxyl but it also closes to hydrogen bonding distance with the Asn564 (H3)
sidechain carbonyl (an interaction present in the GR-DEX complex through its C-11 hydroxyl). For PPT,
this hydrogen bond interaction with the Asn564 amide C=O is present through its C-20 hydroxyl
group. The C-20 hydroxyl group of PPD, however, is not involved in any hydrogen bond interactions
although it is close to, but not within hydrogen bonding distance of the previously mentioned flipped
sidechain C=O of Gln642 (H7). Lastly, the C-6 hydroxyl of PPT, absent for PPD, forms weak hydrogen
bond contact with the Met601 (H5) sidechain S atom. The tail group –CH2CH2CHC(CH3)2 of both
PPD and PPT ligands is orientated between H7 and H11, and with no bad contacts.
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2.2. PPD and PPT Induce GR Nuclear Translocation
Structural similarities of PPD and PPT with corticosteroids as well as results from the induced-fit
docking analysis (Table 1), showing potential binding of PPD and PPT to GR, prompted us to explore
the efficacy of PPD and PPT to induce GR nuclear translocation at cellular level. As shown in Figure 2,
immunocytochemistry analysis of GR in HeLa cells, cultured in hormone-free medium, and treated
with DEX, PPD or PPT, and statistical analysis of the results by one way ANOVA followed by Tukeys’
post-hoc test showed statistically significant increase in GR nuclear localization by DEX, PPD and
PPT compound (F = 143.3; Fcrit = 2.7; DFbetween groups = 3; DFwithin groups = 106; DFtotal = 109, p < 0.001).
10 µM of PPD and PPT caused approximately 50 and 60 %, respectively, nuclear localization of
GR, compared to the 85 and 40 % nuclear GR localization of the DEX-induced and vehicle-treated
HeLa cells, respectively (Figure 3). In order to assess the dose dependency of this effect, HeLa cells,
grown in hormone-free medium, were transiently transfected with the pEGFPC2GR construct [8] and
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subsequently treated with PPD or PPT compound, at concentrations range from 0.1 µM to 20 µM.
Fluorescence microscopy analysis of the specimens revealed that concentrations higher than 0.1 µM
are capable of inducing GR nuclear translocation (Figure 4). Quantification of the results showed a
tendency of increase in GR nuclear translocation by the increased concentration of the PPT compound
(Supplementary Figure S1). Statistical analysis of the results with one-way ANOVA followed by Fisher
LSD test (but not with the Post Tukeys’ post-hoc test) showed statistical significant increase in GR
nuclear translocation in group of cells treated with various concentrations of the PPT compound
(F = 40.8; Fcrit = 1.8; DFbetween groups = 13; DFwithin groups = 153; DF total = 166, * p < 0.001).
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hormone-free medium for 48 hr were subsequently treated, with 10 µM of PPD or PPT, 1 µM
DEX, for 2 hr . Control cells ere treated with dimethyl sulfoxi e (DMSO) (diluent of PPD and PPT)
an EtOH (diluent of DEX), at the same dilution as steroid treated cells. C lls wer then washed in
phosphate-buff red saline (PBS), fixed i methanol- cetone and subjected to immunochemistry analysis
usi g antibodies against GR (GR-H300), anti-rabbit secondary antibodies Alexa Fluor® 4 8 conjugated
(Green) and the Hoechst 3 ,342 (Blue) dye for nuclear stai i . i i t µM. ( ) l tive R
nuclear localization is express d as percentage of the total c rrected fluorescenc of GR nuclear staining
per the total corrected fluorescence of total GR cellular staining, assessed as described in experimental
section. Data are expressed as mean ± S.D. (n > 20), *** p < 0.001, compared to control.
Int. J. Mol. Sci. 2019, 20, 94 6 of 19
Int. J. Mol. Sci. 2018, 19, x 6 of 19 
 
staining per the total corrected fluorescence of total GR cellular staining, assessed as described in 
experimental section. Data are expressed as mean ± S.D. (n > 20), *** p < 0.001, compared to control. 
 
Figure 4. Dose-dependent PPD- and PPT- induced nuclear localization of GR. HeLa cells grown on coverslips, 
in hormone-free DMEM for 72 hrs, were subsequently transiently transfected with a pEGFPC2GR construct [8] 
and the next day cells were further incubated for 2 hrs with various concentrations of PPD or PPT, range from 
0.1 μM to 20 μM, or 1 μM DEX. Cells were then washed with PBS, fixed in methanol acetone mounted in 
polyvinyl alcohol-based antifading medium and proceeded to microscopy analysis. Representative images of 
fluorescence microscopy analysis of GFPGR localization in HeLa cells, treated with various concentrations of 
PPD and PPT are presented. Bars indicate 30 μΜ. Quantification of the results is presented in Supplementary 
Figure S1. 
2.3. PPD and PPT Suppress the DEX Induced GR Transactivation 
PPD- and PPT- induced GR nuclear translocation prompted us to evaluate the effect of both 
compounds on GR transcriptional activation. Luciferase reporter gene assays, using a MMTV-GRE 
(Mouse Mammary Tumor Virus-Glucocorticoid Response Elements) promoter-driven luciferase 
construct [37], revealed that the PPT and PPD-induced GR nuclear translocation was not 
accompanied by GR transcriptional activation (Figure 5A). As was expected, incubation of HeLa cells 
with 1 μΜ DEX caused approximately 4-5 fold statistically significant increase in GR transcriptional 
activity (F = 135.3; Fcrit = 4.0; DFwithin groups = 75; DFtotal = 80, n > 10, p < 0.001, analysis of the results by 
two way ANOVA followed by Tukeys’ post-hoc test). Interestingly, PPT and PPD showed a 
suppressive effect against the DEX-induced GR transactivation. Incubation of the cells with DEX 
when combined with PPD and PPT showed approximately 20% inhibition of the DEX-induced GR 
transactivation. (F = 5.6; Fcrit = 3.1; DFwithin groups = 75; DFtotal = 80, n > 10, p < 0.01). In addition, evaluation 
of the effect of the PPD and PPT compound on the GR target, gluconeogenic phosphoenolopyruvate 
carboxykinase (PEPCK) enzyme [38] showed decrease in PEPCK expression, in the presence or 
absence of DEX in HeLa cells, cultured in hormone-free medium (Figure 5B). Likewise, similar 
analysis in hepatocarcinoma HepG2 cells showed that treatment of the cells with PPT caused 
approximately 20–30% reduction in PEPCK protein levels, compared to control vehicle-treated cells 
(Figure, 5C, Supplementary Figure S3). This effect may be associated with the observed reduction in 
GR protein levels in HeLa and HepG2 cells treated either with DEX or the PPD and PPT compounds, 
rather than their possible antagonistic effect on DEX transactivation (Figure 5C, Supplementary 
Figure S3). 
Figure 4. Dose-dependent PPD- and PPT- induced nuclear localization of GR. HeLa cells grown
on coverslips, in hormone-free DMEM for 72 hrs, were subsequently transiently transfected with
a pEGFPC2GR construct [8] and the next day cells were further incubated for 2 hrs with various
concentrations of PPD or PPT, range from 0.1 µM to 20 µM, or 1 µM DEX. Cells were then washed
with PBS, fixed in methanol acetone mounted in polyvinyl alcohol-based antifading medium and
proceeded to microscopy analysis. Representative images of fluorescence microscopy analysis of
GFPGR localization in HeLa cells, treated with various concentrations of PPD and PPT are presented.
Bars indicate 30 µM. Quantification of the results is presented in Supplementary Figure S1.
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Fcr t = 4.0; DFwithin groups = 75; DFtotal = 80, n > 10, p < 0.0 1, analysis of the results by two way ANOVA
follo ed by Tukeys’ post-hoc test). Interestingly, PPT and PPD showed a suppressive effect against
the DEX-induced GR transactivation. Incubation of the cells with DEX when combined with PPD and
PPT sh wed approximately 20% inhibition of the DEX-induced GR transactivation. (F = 5.6; Fcrit = 3.1;
DFwithin groups = 75; DFtotal 80, n > 10, p < 0.01). In ddition, evaluation of the effect of the PPD
and PPT compound on the GR target, gluconeogenic phosphoenol pyruvate carboxyki ase (PEPCK)
enzyme [38] showed decrease in PEPCK expression, in the presence or absence of DEX in HeLa
cells, ultured in hormone-free medium (Figure 5B). Lik wise, similar analysis in hepatocarcinoma
HepG2 cells showed that tre tm nt of the cells ith PPT caused appr ximately 20–30% redu tion in
PEPCK protein levels, compared to control vehicl -treat d cells (Figure 5C, Supplementary Figure S3).
This effect may be associated with the observed reduction in GR protein levels in HeLa and HepG2 cells
treated ither with DEX or the PPD and PPT compounds, rat er than their possible antagonistic effect
on DEX transactivation (Figure 5C, Supplementary Figure S3).
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2.4. Transcriptional Inactivation of NF-κBby PPD and PPT via Potential Activation of GR
Transrepression Activity
Anti-inflammatory activity of PPD and PPT was assessed via evaluation of their actions on
NF-κB activity. Thus, effect of PPD and PPT on the NF-κBactivity was assessed in GR-positive HeLa
(Figure 6A,B) and HEK293 (Figure 6C) cells, as well as in GR low level COS-7 cells (Figure 6D),
grown in hormone-free medium, and transiently transfected with a NF-κB-Luciferase (NF-κB-Luc)
and a β-galactosidase construct [37]. HeLa (Figure 6A,B) and HEK293 (Figure 6C) were subsequently
treated with Tumor Necrosis Factor α (TNF α) (10 ng/mL) or equal volume of PBS, in the presence
or absence of 1 µM or 10 µM of PPD or PPT, 1 µM DEX or DMSO/EtOH vehicle (Figure 6A,B).
Measurements of luciferase activity revealed that TNF α induced statistically significant increase in
NF-κB transcriptional activation, in both cell lines ((A) F = 214.4; Fcrit = 4.5; (B) F = 78.1; Fcrit = 3.9; (C)
F=276.4; Fcrit = 4.5, p < 0.001), whereas DEX caused statistically significant suppression of the TNF α -
induced transcriptional activity of NF-κB, by 40–55 %. A similar effect was also observed by PPD and
PPT ((A) F = 35.2; Fcrit = 3.2; DFwithin groups = 16, DFtotal =23; (B) F = 10.9; Fcrit = 2.7; DFwithin groups = 92;
DFtotal = 99; (C) F = 4.4, Fcrit = 3.2; DFwithin groups = 16; DFtotal = 23). PPD suppressed the TNF α-induced
NF-κBactivity by 28–45%, whereas PPT exerted 38–65 % inhibition. Our results indicate that increase
in PPD and PPT concentration from 1 µM to 10 µM did not substantially strengthen their inhibitory
activity. Evaluation of the anti-inflammatory effect of 10 µM of PPD and PPT, via transcriptional
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inactivation of the TNF α-activated NF-κB, was not observed in GR low level COS-7 cells (Figure 6D)
(F = 87.4, Fcrit = 4.5, (−TNF/+TNF); F = 0.8, Fcrit = 3,3 (Treatment); F = 2.0, Fcrit = 3.2, (TNF/Treatment);
DFwithin groups = 16, DFtotal = 23); “Treatment” corresponds to treatment either with vehicle, DEX, PPD
or PPT), providing circumstantial evidence for the involvement of GR in the PPD- and PPT-induced
NF-κBtranscriptional inactivation. Cytotoxicity analysis in HeLa cells, applying the sulphorodamine
B assay [39], showed that 48 h incubation of HeLa cells with the PPD and PPT compounds, at a
concentration range from 1 µM to 20 µM, caused no statistical significance inhibition in cell growth.
This effect indicates that the observed anti-inflammatory activity of the compounds is not due to any
cytotoxic effect (Supplementary data, Supplementary Figure S2).
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Figure 6. Suppression of the NF-κB transcriptional activity by PPD and PPT in HeLa and HEK293 cells
possibly through regulation of GR signalling. (A,B) Luciferase and β-galactosidase activity was
measured in cell extracts from GR positive HeLa cells cultured in hormone depleted medium,
transiently co-transfected with a NF-κBLuc reporter gene construct and a β-galactosidase reporter
construct and subsequently treated with 1 µM (A) or 10 µM (B) of PPD or PPT and/or 10 nM TNF
α, for 6 hrs. Relative luciferase activity was expressed as normalized luciferase activity against
β-galactosidase activity. Effect of 10 µM of PPD or PPT on NF-κB activity was also evaluated in GR
positive HEK293 cells (C) and in GR low level COS-7 cells (D). Data are expressed as mean ± S.D.
(n = 3–5), * p < 0.05; ** p < 0.01; *** p < 0.001.
2.5. PPD and PPT Induce Mitochondrial-Dependent Apoptosis
In order to evaluate the effects of PPD and PPT on apoptosis, Western blot analysis of
anti-apoptotic and apoptotic molecules such as Bcl2, procaspase 3 and procaspase 9 was performed
in HeLa (Figure 7A) and HepG2 (Figure 7B) cells, treated or not with 1µM DEX and/or 10 µM of
the PPD and PPT compounds, for 48 hrs. As shown in Figure 7, evaluation of the effect of the
PPD and PPT compound on Bcl2 protein level in HeLa and HepG2 cells, showed no remarkable
action. Interestingly, as shown in Figure 7A, DEX, PPD, and PPT compounds caused induction of
the mitochondrial dependent apoptosis, in HeLa cells, as indicated by the observed reduced protein
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level of the uncleaved, non-activated procaspase 9 and procaspase 3, compared to control, vehicle
treated HeLa cells (Figure 7A). The mitochondrial dependent induction of apoptosis by PPT and PPD
was also verified in HepG2 cells, as indicated by the decreased protein level of the uncleaved caspase
9 and caspase 3, upon treatment of the cells with 10 µM of the PPD and PPT compounds. In addition,
a moderate increase in caspase 9 activation is observed upon co-administration of DEX with the PPD
and PPT compounds (Figure 7B).
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Figure 7. PPD and PPT induce mitochondrial dependent apoptosis. Western blot analysis of β-actin,
Bcl2, pro-caspase 3 and pro-caspase 9 protein levels in cell extracts from HeLa (A) and HepG2
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was performed using commercially provided antibodies. Ratios indicate normalization of Bcl2,
pro-caspase 3 and pro-caspase 9 protein levels against β-actin or α-tubulin, as indicated.
3. Discussion
Triterpenoids are structurally diverse organic compounds that exist widely as natural products.
These compounds are precursors of steroids in both plants and animals [40]. Triterpenoid saponins,
known as ginsenosides, are biologically active chemical in ginseng, a traditional herbal adaptogen,
of the genus Panax (Araliance Family) that has been widely used in traditional medicine
because of its medical properties [31]. Ginsenosides biological activities include antidiabetic
actions, hepatoprotective activity, anti-inflammatory effect, myocardial protection, lipid regulation,
antioxidation, neuroprotection, anti-angiopathy and anti-neurotoxic effects [29,31].
Pharmacological activities of ginsenosides are mainly attributed to their steroidal structure,
which enables them to diffuse across cellular membrane, to enter the cells and to interact with
membranous, cytoplasmic and nuclear target proteins, modulating their activities and cellular
functions. Thus, experimental data indicate that ginsenosides interferes with signaling pathways such
as phosphotidyloinositol-4,5 bisphosphate 3-kinase/protein kinase B (PtdIns(4,5)P2/Akt) pathway,
signal transducer and activator of transcription 5/peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (STAT5/PPARgamma) pathway, phosphoinositide-3 kinase/protein kinase B
(PI3K/Akt) pathway, AMP-activated protein kinase/c-Jun terminal NH2-terminal kinase (AMPK-JNK)
pathway, NF-κB pathway, endoplasmic reticulum stress, inflammatory, antioxidant and apoptotic
pathways, glucose import and glucose metabolism pathways [29]. Nevertheless, the biochemical and
potential pharmacological mechanisms, as well as the molecular targets of ginsenosides are unclear
and remains to be elucidated.
Due to the structural similarities of ginsenosides with steroid hormones they could be considered
as potential modulators of steroid hormone receptors. Accumulating evidence indicate that
ginsenosides are involved in the regulation of nuclear receptors [41]. Thus, it has been shown that
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PPD- and PPT- type ginsenosides are capable of binding to GR [42–46]. The efficacy of binding is
lower to that of the synthetic glucocorticoid DEX, and more importantly, experimental data, resulting
from a comparative time-resolved fluorescence resonance energy transfer competitive ligand binding
assay, showed that the number of glycosylated groups in ginsenosides is accompanied by a decrease in
receptor binding potency [28]. In addition, accumulating studies showed that ginsenosides metabolites
had greater biological effects than ginsenosides [30]. As regards the effect of certain PPT- and PPD-
type ginsenosides on GR transactivation activity and transrepression activity, conflicting data are
presented [28,43,46–52]. Nevertheless, to our knowledge, there is a lack of data on the effect of the
aglycone form of PPT- and PPD- type compounds on GR transactivation and transrepression activities.
Our data from induced fit docking analysis showed that the aglycone form of the PPD- and PPT-
type compound is capable of binding to GR ligand binding domain. In fact, comparable binding
strengths to DEX are predicted as well as similar interactions with GR LBD helices/residues, previously
cited as important for nuclear translocation [26,36]. As we have previously stated [26], the crucial
factor is the ligand-dependent structural reorganizations of the LBD that allow a receptor to function as
a more potent activator. PPT is predicted to bind slightly stronger than PPD in the predicted docking
models (Table 1). The potential efficacy of PPD and PPT to bind to GR ligand binding domain is
in agreement with the results from the comparative study of [28] and is further confirmed by our
data showing that PPD- and PPT- induced GR nuclear translocation at cellular lever, in HeLa cells.
The observed more favorable PPT- translocation is also consistent with predicted stronger interactions
with H3 through direct hydrogen bonding interaction with the Asn564 amide C=O. PPD and more
effectively the PPT compound are capable of inducing endogenous as well as gene delivered-induced
GR nuclear translocation at concentrations ranging from 0.1 µM to 20 µM.
PPD- and PPT- induced nuclear translocation was not accompanied by GR transactivation,
as indicated by the results from the GRE-driven luciferase reporter gene expression assay, showing
no PPD- and PPT- induced GRE driven luciferase gene expression. Nevertheless, both compounds
were capable of suppressing the DEX-induced GR transactivation. Moreover, PEPCK protein level
were considerably decreased in HeLa cells, cultured in hormone-free medium, and treated with
PPT or PPD in combination or not with DEX. In addition, moderate reduction in PEPCK protein
levels by PPT, but not by PPD, was observed in HepG2 cells. Since liver is the main gluconeogenic
organ, the discrepancy of the results in the two cell lines may be attributed to the more pronounced
gluconeogenetic properties, of the hepatocarcinoma HepG2 compared to that of the HeLa cells, relied
on the differential expression of GR and its co-activators or co-repressors, as well as, to the differential
recruitment of these factors in the GR transcription complex, triggered by binding of PPD or PPT to
GR [53]. Our observation of the reduction of PEPCK protein level by PPD and PPT is consistent
with previous findings demonstrating that certain ginsenosides such as Rb1 (multiglycosylated
PPD-type ginsenoside) induced reduction in hepatic glucose production by suppressing the expression
of the gluconeogenic glucose 6-phosphate phosphatase and phosphoenolpyruvate carboxykinase
enzymes [54]. The reduction in PEPCK protein levels in PPD- and PPT- treated cells could be associated
with the reduction in GR protein levels, observed in HepG2 cells, upon treatment with the PPD and
PPT compound. Reduction in GR protein levels by the PPD compound was also verified in HeLa cells.
Reduction in GR protein levels by PPT and PPD may be the result of the activation of AMP-activated
protein kinase, (AMPK). Activation of the AMPK is demonstrated to take place upon conditions of
glucocorticoids-stress [55], but also upon treatment with the Rb1 ginsenoside [54]. In addition, in line
with our observation, and in support of the notion of a potent GCs-like activity of the compounds,
reduction in GR protein level, in the presence of DEX at concentrations higher than 10−7 M, has also
been reported in various types of cells, including HeLa cells [26,56–58]. The ligand–induced repression
of the GR gene is proposed to be mediated by an NCoR1 (nuclear repressor co-repressor 1) repression
complex formation [59], however, GCs non-genomic mechanisms of action could also be involved in
this action. Thus, although DEX induced GR transcriptional activation, this effect is compensated by
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the DEX-induced reduction in GR protein levels, resulting in not profound increase in PEPCK protein
levels compared to control cells.
The antidiabetic-hypoglycemic and anti-inflammatory activity of PPD- and PPT- type ginsenosides
has been known for a very long time. The molecular mechanisms underlying these actions are unclear
and under investigation. Thus, multiglycosylated PPD- and PPT-type ginsenosides, such as Rb1 and
Rg1, respectively, have been shown to exert antihyperglycemic activity via induction of increase in
insulin sensitivity and insulin uptake [60,61], suppression of insulin resistance [62], reduction in food
uptake and body weight [54], increase in membrane translocation of glucose transporters GLUT1 and
GLUT4 [61,63], increase in glucose uptake [54] and suppression of the gluconeogenic enzymes glucose
6-phosphate and PEPCK expression [54,64].
Even though PPD and PPT did not induce GR transactivation, both compounds were capable
of suppressing the TNF-α -induced NF-κB activity in HeLa- as well as in HEK293- GR positive cells.
1 µM of the compounds were approximately as effective as 10 µM to suppress the TNF-α -induced
NF-κB activity in HeLa cells, in agreement with results from fluorescence microscopy analysis, showing
that concentrations higher than 1 µM of the compounds are effective enough to trigger the GR nuclear
translocation. Similar effects have also been observed by the synthetic glucocorticoid, DEX. Thus, the ability
of DEX to fully activate GR nuclear translocation and transcriptional activation, in a broad range of
concentrations, varying from nM to µM, has been reported [26,65]. Furthermore, the PPT compound,
that is more active in activation of the GR nuclear translocation, is also more active in suppression of
the NF-κB activity. Interestingly, PPT is as effective as DEX, causing approximately 40% reduction in
the TNF-α induced NF-κBactivity. The suppressive effect of the compounds in not attributed to any
inhibitory effect of the compounds on cell growth, as indicated by results from the sulphorodamine B
assay. Moreover, the inhibitory effect of PPD and PPT on the NF-κBactivity is abolished in GR low level
COS-7 cells, providing circumstantial evidence for the involvement of GR in this process.
The suppressive effect of PPD and PPT on NF-κBactivity in combination with their inability to
induce GR transactivation renders them potential promising lead molecules for the development
of novel potent drugs with anti-inflammatory activity but with no or reduced side effects.
Moreover, the possible additive effect of the compound when administered in combination with
other GR modulators, that also exert GR transrepression activity, may be of significant pharmacological
importance. Thus, co-administration of the PPD and PPT compounds with RU486, the well-known GR
antagonist which also exert immunosuppressive actions, through suppression of NF-κB, AP1 activity
and cytokines production [66–68], could possibly lead to further enhancement of the PPD and PPT
anti-inflammatory activity. Nevertheless, due to a possible competition between PPD/PPT and
RU486 for binding to GR, none or just a partial reversal of the suppressive PPD or PPT effect is also
likely to occur. In addition, taking into account the importance of the differential conformational
GR changes induced upon binding, as well as other factors, such as type of the cell, presence or
absence of corepressors/coactivators or other regulatory molecules, that affect the final outcome of
the co-administration of the compound [20], a cell type-specific action could be arise with potential
pharmacological importance.
In line with our observations, multiglycosylated PPD- and PPT-type ginsenosides such as Rb1 and
Rg1 have been shown to exert anti-inflammatory activity, through (a) reduction in pro-inflammatory
cytokines and mediators, including TNF-α, interleukins IL-6, IL-1β, (b) regulation of NF-κB and JNK
signaling pathway, and (c) increase in nitric oxide synthesis and release [69–71]. Glucocorticoids signaling
also involve interference with these pathways [72,73], thus binding of PPD and PPT to glucocorticoid
receptor and regulation of its action may be at least in part the causative for these effects.
Glucocorticoids are also well known for their tissue and cell type-specific pro-apoptotic actions [74]
rendering them effective and widely used drug for the treatment of certain lyphoproliferative disorders
and to alleviate side effects induced by chemotherapy or radiotherapy in nonhematologic cancer types [14].
In this study we showed that PPD and PPT compound exert apoptotic activities, which are
probably mitochondrial-mediated as indicated by the activation of caspase 9 and 3 upon PPT and PPD
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incubation of HeLa and HepG2 cells. In addition, co-incubation of HepG2 cells with DEX and the PPD
or PPT compound caused increase in procaspase 9 indicating, cell type-specific interference of PPD
and PPT compounds with GR signaling. The observed induction of apoptosis is indicated to be at early
stage, since reduction in procaspase 9 protein level is higher than that of the pro-caspase 3, in the case
of HepG2 cells, and also, no statistical significance inhibition of HeLa cells growth by the PPD and PPT
compound was observed, at this time point. The exact mechanism of induction of apoptosis remains
to be elucidated. However, it is possibly related to the steroid-like activities of the compounds.
To conclude, in this study, we provide evidence that glucocorticoid receptor may constitute, among
others, a potential molecular target for PPD and PPT compounds, to drive their pharmaceutical actions.
Thus, we showed that PPD and PPT compound can effectively bind to GR and activate its nuclear
translocation. Activated GR exert transrepression activity, suppressing NF-κB activation, whereas no
transactivation of GR was observed. Moreover, reduction in PEPCK expression by PPD and PPT was
observed, possibly due to the induced reduction in GR protein levels. To our knowledge this is the
first study to describe potent anti-hyperglycemic, anti-inflammatory actions and apoptotic activities of
the aglycone form of the PPD- and PPT-type ginsenoside, revealing also potential dissociative activity
of PPD and PPT compound on GR transcriptional activation. Although further analysis is required to
delineate the exact mechanisms of actions and interfering of PPD and PPT with GR signaling, our study
contribute to the establishment of new lead molecules for the development of selective glucocorticoid
receptor agonists with potential for therapeutic use as anti-inflammatory and anticancer drug, with
reduced side effects.
4. Materials and Methods
4.1. Chemicals
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and lipofectamin
2000 were obtained from Invitrogen (Life technologies corporation, Grand island, NY, USA).
Molecular weight protein markers were from Fermentas (Thermo Fisher Scientific GmbH, Frankfurt,
Germany) complete protease inhibitors cocktail were purchased from Roche (Mannheim, Germany)
and TNFα was purchased from Immuno Tools (Friesoythe, Germany) All other chemicals including
dexamethasone (DEX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). PPD and PPT were
purchased from Extrasynthese, Genay Cedex, France.
4.2. Antibodies
The GR-H300 affinity purified polyclonal GR antibody, which recognizes an epitope corresponding
to amino acids 121-420 of human GR, and was commercially provided by Santa Cruz Biotechnology,
was used. Monoclonal antibodies against β-actin (Sigma Aldrich, St. Louis, MO, USA) and caspase
9 (Cell Signalling Technology, Leiden, The Netherlands), and rabbit polyclonal antibodies against
phosphoenolpyruvate carboxykinase (PEPCK) (Santa Cruz Biotechnology, Inc, Europe, Heidelberg,
Germany), caspase 3 (Abcam, Cambridge, United Kingdom), Bcl-2 (Cell Signalling Technology, Leiden,
The Netherlands) were also applied.
4.3. Cell Lines-Cell Culture
The human hepatocarcinoma HepG2 and HEK293 cells were obtained from the American type
culture collection (ATTC). HeLa and COS-7 cells were a kind gift from Dr. M Alexis, from the National
Hellenic Research Foundation (NHRF) Greece. All cell lines were maintained in DMEM, supplemented
with 10% FBS, 2 mM glutamine, and 100 Units/mL penicillin/streptomycin. Cells were cultivated at
37 ◦C in 5% CO2 humidity. 48–72 hrs before treatment, cells were cultured in phenol red free-DMEM
medium supplemented with 10% charcoal-dextran- stripped FBS (charcoal inactivated FBS), 2 mM
glutamine, and 100 Units/mL penicillin/streptomycin.
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4.4. Immunofluorescence Microscopy
Cells grown on coverslips, in DMEM hormone-free medium (DMEM without phenol red
supplemented with 10% charcoal inactivated serum) for 48 hrs. Cells were then transiently transfected
with a pEGFPC2GR construct [8]. After 24 hrs, cells were subjected to 2 hrs treatment with PPD
or PPT at concentrations range from 0.2 µM to 20 µM, or 1µM DEX. Cells were then washed with
PBS, fixed for 10 min at −20 ◦C in methanol, transferred to acetone (−20 ◦C) for 2 min, briefly
air-dried and mounted in polyvinyl alcohol-based anti-fading medium. In immunocytochemistry
experiments, cells grown on coverslips, in DMEM without phenol red supplemented with 10% charcoal
inactivated serum, were incubated either with 10 µM PPD/PPT or 1 µM dexamethasone (DEX), for 1 hr,
at 37 ◦C, washed with PBS, and fixed in methanol-acetone (−20 ◦C). After three washings (5 min each),
immunocytochemistry was proceeded using primary GR antibodies (final dilution of 1:50), appropriate
secondary antibodies conjugated with Alexa fluor 488, provided by Invitrogen (Life technologies
corporation, Grand island, NY, USA), diluted 1/500, and 1 µM Hoechst 33,342 (Sigma-Aldrich, St.
Louis, MO, USA). Specimens were mounted in polyvinyl alcohol-based anti-fading medium [8].
Cell specimens were observed with a Leica 2000 DM microscope (Leica, Heerbrugg, Switzerland).
Images were obtained with the optiMOS camera (Qimaging, Surrey, BC, Canada) which kindly
donated by the Bodossaki Foundation, Greece. Quantifications of the relative GR nuclear staining
was performed by the use of the ImageJ v1.47 program (NIH, Bethesda, MD, USA) as previously
described [75]. Briefly, in each individual cell two areas of interest were drawn. One based on total
green fluorescence staining (total) and the other based on Hoechst staining (nuclear). Mean green
fluorescence and integrated density was measured along with several adjacent background readings.
The total corrected fluorescence of area of interest (TCF) = integrated density – (selected area × mean
fluorescence of background readings), was calculated. Relative GR nuclear localization is expressed as
percentage of the nuclear TCF of GR staining per the TCF of total GR cellular staining.
4.5. NF-κB and GR Activity
NF-κB and GR transcriptional activity was measured applying luciferase reporter gene assay.
Briefly, HeLa cells grown on 24-well plates were co-transfected, using Lipofectamin 2000, with a
NF-κB-Luciferase (NF-κB-Luc) (for assessment of NF-κB activity), or an MMTV-GRE (Glucocorticoid
response elements of the murine mammary tumour virus DNA) promoter-driven luciferase construct
(GR-Luc reporter gene construct) (for assessment of GR activity) and a β-galactosidase reporter
construct [8,37]. The next day cells were triggered either by TNF α (tumour necrosis factor α; 10 ng/mL)
for 6 hrs (for assessment of NF-κB activity), or by 1 µM DEX (for assessment of GR activity), in the
presence or absence of the indicated amounts of PPD, PPT or DEX. Subsequently, cells were lysed
in report lysis buffer (Promega Coorporation, Madison, USA), and the enzymatic activities of the
expressed luciferase and β-galactosidase were measured [37]. The light emission was measured using
a chemiluminometer (LB 9508, www.berthhold.com). Relative luciferase activity was expressed as
normalized luciferase activity against β-galactosidase activity (RLU).
4.6. Electrophoresis and Western Blotting
Cells grown on 6 well plates, for 48 hrs in hormone depleted medium, were incubated for
additional 48 hrs with 10 µM of PPD, 10 µM of PPT and/or 1 µM DEX. Cells were washed in PBSX1,
lysed in buffer A (20 mM Tris pH:7.5, 250 mM NaCl, 0.5 % Triton, 3 mM EDTA) supplemented
with cocktail preotease inhibitors (Rosche, Germany). After Bradford protein determination [76], cell
extracts were electrophoresed in discontinuous SDS-PAGE and Western blotted with specific antibodies
against GR, β-actin, α-tubulin, PEPCK, Bcl-2, caspase 3 and caspase 9 as previously described [77].
β-actin or α-tubulin expression levels were evaluated for the normalization of the PEPCK, GR, Bcl-2,
procaspases-3 and -9 expression levels. Enhanced chemiluminescence was used for the detection of
the protein bands.
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4.7. Statistical Analysis
All results are expressed as mean ± SD. Data were analysed by independent t-test or by One-Way
analysis of variance (ANOVA) (Figure 3) or Two-Way ANOVA (Figures 5 and 6) followed by Tukeys’s
post-hoc test using StatPlus software. Differences were considered significant at a two tailed p
value < 0.05. Further details for statistics are given in the Supplementary Information, Section 4: Full
statistics—Details on the statistical analysis of the results.
4.8. Induced-Fit Docking Calculations
The ligands (PPD, PPT and DEX) were prepared for docking calculations using LigPrep v3.6 [78]
with the OPLS3 forcefield [79]. Initial 3D structures of the two triterpenoids were downloaded from
PubChem (https://pubchem.ncbi.nlm.nih.gov/). The GR protein was prepared for docking using
the solved crystallographic complex (PDB code: 3BQD) with deacylcortivazol, exploiting its more
open binding pocket for the study of bulkier ligands [26,80], and previously successfully applied to
investigate the binding properties of echinocystic acid and its 3-O-glucoside derivative [26].
The initial setup of the GR structure for calculations was performed using Schrodinger’s “Protein
Preparation Wizard” [78]. Water molecules within 5 Å of the deacylcortivazol ligand were initially
retained but deleted for subsequent docking. Bond orders were assigned, hydrogen atoms added,
with protonation states for basic and acidic residues based on calculated PROPKA pKa values at pH 7.
Subsequent optimization of hydroxyl groups, histidine sidechain C/N atom “flips” and protonation
states, and side-chain O/N atom flips of Asn and Gln was based on optimizing hydrogen bonding
patterns. Finally, an “Impref” minimization was performed using the OPLS3 force field [79] to remove
any steric clashes/bad contacts but with heavy atoms constrained to within 0.3 Å (RMSD) of their
original positions.
IFD calculations [78] consisted of three stages. In Stage I, initial docking using Glide v7.2 in SP
(standard precision) mode was performed with docking grids of dimensions 29 Å × 29 Å × 29 Å
centred on the deacylcortivazol ligand, with a maximum of 20 poses saved. Stage II was a Prime
v4.5 induced-fit using OPLS3 with protein residues within 7.5 Å of the initial ligand poses refined [26].
In the final Stage III, up to 20 structures from Stage II within 30 kcal/mol of the lowest energy structure
were used for Glide-XP (extra-precision) ligand re-docking calculations. The final protein-ligand
geometries were analyzed in terms of structure and binding interactions, ligand re-docking GlideScores
(GSs), as well as IFDScores (re-docking GS + 5% Prime energy).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/1/
94/s1.
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Abbreviations
Akt protein kinase B
AMPK AMP activated protein kinase
ANOVA Analysis of Variance
DEX Dexamethasone
GCs Glucocorticoids
GLUT glucose transporters
GR glucocorticoid receptor
GRE Glucocorticoid Response Element
IFD Induced-Fit Docking Analysis
IL Interleukin
JNK c-Jun terminal NH2-terminal kinase
NF-κB Nuclear factor-kappa beta
LBD Ligand Binding Domain
MMTV Mouse Mammary Tumor Virus
PEPCK Phosphoenolopyruvate Carboxykinase
PI3K phosphoinositide-3 kinase
PPARgamma peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PPD Protopanaxadiol
PPT Protopanaxatriol
PtdIns(4,5)P2 Phosphotidyloinositol-4,5 bisphosphate 3-kinase
SEGRAs Selective Glucocorticoid Receptors Activators
SEGRMs Selective Glucocorticoid Receptors Modulators
Stat3 Signal Transducer and Activator of Transcription – 3
STAT5 signal transducer and activator of transcription 5
TNFα Tumor Necrosis Factor α
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